Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

METRONIDAZOLE & NYSTATIN

All products: general benefit

Other products in the same Health Canada class (G01A) — coverage varies; not interchangeable

  • Metronidazole (Noritate): general benefit, Not a benefit

Flagystatin · DIN 01926829 · 500mg & 100000U · Vag suppository

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Flagystatin · DIN 01926829 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Marketed since 2007-12-11 · brand FLAGYSTATIN · ATC G01AA51 NYSTATIN, COMBINATIONS, G01AA51 NYSTATIN, COMBINATIONS · form Ovule · route Vaginal · ingredients NYSTATIN 100000 UNIT, METRONIDAZOLE 500 MG · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Flagystatin: Formulary list price $3.8510/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.8510 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12654 · Verify on the e-Formulary ↗ (DIN 01926829)

Source record
DIN 01926829: Flagystatin Raw flags: sec3=Y Item: 840416020; group id 831; item number 2024; lccId None; manufacturer id SAV Source form: Vag Sup; strength: 500mg & 100000U Recorded listing: General benefit Source prices (unrounded): $3.8510; ministry $3.8510 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01926829 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12654
Shortage status: resolved shortage (ended 2025-11-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926829
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (84:04:16 Other Anti-Infectives) and how they are covered

Matched class: 84:04:16 Other Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: SILVER SULFADIAZINE Some products covered without a code (check the product listing): METRONIDAZOLE 84:04:16 Other Anti-Infectives

METRONIDAZOLE

· 5 products · General benefit (3), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 1%, 0.75%, 10% · Top Cr, Top Gel, Vag Cr-App

SILVER SULFADIAZINE

· 2 products · General benefit · strengths: 1% · Cr, Cr-50g Pk

POVIDONE - IODINE

· 2 products · Listed, not a benefit · strengths: 10% · Top Sol Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:16
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:08 Fungicides, 84:04:12 Parasiticides Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. INDICATIONS FLAGYSTATIN (metronidazole and nystatin) is indicated for: • Mixed vaginal infection due to Trichomonas vaginalis and Candida albicans. FLAGYSTATIN has antibacterial and antifungal properties. To reduce the development of drug-resistant bacteria/fungi and maintain the effectiveness of FLAGYSTATIN and other antibacterial/antifungal drugs, FLAGYSTATIN should be used only to treat proven or strongly suspected mixed vaginal infections. 1.1. Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics: No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00085865.PDF PM date: 2026-08-21 Source product: FLAGYSTATIN; DIN 01926829; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.